Avid Bioservices Inc (CDMO)

[biopharm]

Westjtter, yes and quick response ...not many are left that remembered OxiGene

Now, if back in 2002 era Peregrine was able to utilize any new scientific findings from the collaboration...there are Biomarkers that are in play that also give Pererine, now Avid Bioservices CDMO that will be key.

http://ir.avidbio.com/news-releases/news-release-details/peregrine-and-oxigene-conclude-arcus-therapeutics-llc-joint


February 28, 2002 at 12:00 AM EST
Peregrine and OXiGENE Conclude ArcusTherapeutics LLC Joint Venture; Companies Reacquire Full Rights to Respective Vascular Targeting Technologies TUSTIN, Calif., Feb 28, 2002 (BW HealthWire) -- OXiGENE Inc. (Nasdaq:OXGN)(SSE:OXGN) and Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) today announced an agreement to conclude their Arcus Therapeutics, LLC joint venture (Arcus).
Under the terms of the agreement, Peregrine will pay OXiGENE $2,000,000 and will reacquire full rights and interest to the vascular targeting platform it contributed to the joint venture, as well as any new discoveries to its contributed technology.

OXiGENE will reacquire full rights and interest to its vascular targeting technology including any new discoveries based on its contribution. The joint venture will be concluded after all technology has been distributed to its respective owners.
...
...

Seems like so much more is going on also...that JP Morgan types don't want some to know ....though some new IIS will find out that buying CDMO in $7 range is true breadcrumbs ...so well worth the investment

I also noticed the ties to Moffitt ...and there are other places as well, that know the true value of the IP assets have yet to even be realized

I would strongly recommend that all read R66 posts from last week and forward any complaints to DOJ, because sometimes one may find out that some even in other Authorities "may" not have it in their interest to pursue open cases ...though with Moffitt new of Alan List and Thomas Sellers gone from Moffitt, I do believe PS Targeting and all other IP assets / Biomarkers will be known to others soon

Happy New Year to all : )

____


http://ir.avidbio.com/news-releases/news-release-details/peregrine-pharmaceuticals-announces-three-abstracts-accepted-0


April 14, 2015 at 8:00 AM EDT
TUSTIN, Calif., April 14, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that two preclinical abstracts and one clinical translation abstract are scheduled for poster presentations at the 106th Annual Meeting of the American Association for Cancer Research (AACR), to be held April 18-22, 2015 in Philadelphia, Pennsylvania. Data to be presented include studies investigating the therapeutic potential of Peregrine's phosphatidylserine (PS)-targeting antibodies when administered in combination treatment regimens with approved and developmental cancer immunotherapies and translation data in patients with lung cancer. Peregrine's lead PS-targeting antibody, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other
treatment combinations and additional oncology indications.

Abstract details:

Abstract Number: 274

Presentation Title: Bavituximab modulates tumor microenvironment and activates CD8+ tumor infiltrating lymphocytes in a patient-derived 3D ex vivo system of lung cancer
Presentation Time: Sunday, April 19, 2015, 1:00 PM - 5:00 PM Eastern Daylight Time
Location: Section 13
Poster Board Number: 2
Author Block: Soner Altiok1, Melanie Mediavilla-Valera2, Jenny Kreahling2, David Noyes2, Tiffany N. Razabdouski2, Nikoletta L. Kallinteris3, Joseph Shan3, Scott Antonia2. 1Nilogen Oncosystems, Tampa, FL; 2Moffitt Cancer Center, Tampa, FL; 3Peregrine Pharmaceuticals, Inc, Tustin, CA